S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Costco vs Amazon: an end of the year showdown
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Bear or bull market, this highly successful trader has shocking new forecast  (Ad)
Closing prices for crude oil, gold and other commodities
Discount Retailers Could Make Good Bargain Stocks
Bear or bull market, this highly successful trader has shocking new forecast  (Ad)
How major US stock indexes fared Friday 12/9/2022
K-pop star among 8 to join Japan tycoon Maezawa's moon trip
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Costco vs Amazon: an end of the year showdown
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Bear or bull market, this highly successful trader has shocking new forecast  (Ad)
Closing prices for crude oil, gold and other commodities
Discount Retailers Could Make Good Bargain Stocks
Bear or bull market, this highly successful trader has shocking new forecast  (Ad)
How major US stock indexes fared Friday 12/9/2022
K-pop star among 8 to join Japan tycoon Maezawa's moon trip
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Costco vs Amazon: an end of the year showdown
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Bear or bull market, this highly successful trader has shocking new forecast  (Ad)
Closing prices for crude oil, gold and other commodities
Discount Retailers Could Make Good Bargain Stocks
Bear or bull market, this highly successful trader has shocking new forecast  (Ad)
How major US stock indexes fared Friday 12/9/2022
K-pop star among 8 to join Japan tycoon Maezawa's moon trip
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Costco vs Amazon: an end of the year showdown
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Bear or bull market, this highly successful trader has shocking new forecast  (Ad)
Closing prices for crude oil, gold and other commodities
Discount Retailers Could Make Good Bargain Stocks
Bear or bull market, this highly successful trader has shocking new forecast  (Ad)
How major US stock indexes fared Friday 12/9/2022
K-pop star among 8 to join Japan tycoon Maezawa's moon trip
NASDAQ:ARCT

Arcturus Therapeutics - ARCT Stock Forecast, Price & News

$16.92
-1.12 (-6.21%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$16.92
$18.22
50-Day Range
$14.14
$23.38
52-Week Range
$11.70
$48.75
Volume
428,950 shs
Average Volume
574,383 shs
Market Capitalization
$448.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.25

Arcturus Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
67.0% Upside
$28.25 Price Target
Short Interest
Healthy
11.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.11mentions of Arcturus Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.93) to $0.89 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.54 out of 5 stars

Medical Sector

131st out of 1,034 stocks

Pharmaceutical Preparations Industry

48th out of 504 stocks

ARCT stock logo

About Arcturus Therapeutics (NASDAQ:ARCT) Stock

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARCT Stock News Headlines

Why CSL Ltd Stock Could Be Worth a Look (ARCT)
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.
Massive Insider Trade At Arcturus Therapeutics
Citigroup Upgrades Arcturus Therapeutics to Buy
What 4 Analyst Ratings Have To Say About Arcturus Therapeutics
Where Arcturus Therapeutics Stands With Analysts
ARCT Arcturus Therapeutics Holdings Inc.
See More Headlines
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARCT Company Calendar

Last Earnings
11/08/2021
Today
12/10/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
177
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.25
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+67.0%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

Net Income
$-203,670,000.00
Net Margins
-284.78%
Pretax Margin
-284.78%

Debt

Sales & Book Value

Annual Sales
$12.40 million
Book Value
$8.66 per share

Miscellaneous

Free Float
23,261,000
Market Cap
$448.26 million
Optionable
Optionable
Beta
2.51

Key Executives

  • Mr. Joseph E. Payne M.Sc. (Age 50)
    Founder, Pres, CEO & Director
    Comp: $960k
  • Dr. Padmanabh Chivukula (Age 43)
    Founder, Chief Scientific Officer, COO & Sec.
    Comp: $750k
  • Mr. Andrew H. Sassine MBA (Age 58)
    CFO & Director
    Comp: $750k
  • Mr. Lance Kurata
    Chief Legal Officer
  • Dr. Steven George Hughes M.B.A. (Age 54)
    M.D., Strategic Clinical Advisor & Member of Scientific Advisory Board
    Comp: $644k
  • Mr. Keith C. Kummerfeld CPA
    VP of Fin. & Corp. Controller
  • Dr. Dushyant B. Varshney Ph.D.
    Exec. VP & Chief Technology Officer
  • Mr. Deepankar Roy
    Sr. Director of Investor Relations
  • Mr. Kevin T. Skol
    Sr. VP of Bus. Devel. & Alliance Management
  • Dr. Kelly A. Lindert M.D.
    Chief Devel. Officer of Vaccines













ARCT Stock - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ARCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View ARCT analyst ratings
or view top-rated stocks.

What is Arcturus Therapeutics' stock price forecast for 2023?

8 Wall Street analysts have issued 12-month price objectives for Arcturus Therapeutics' stock. Their ARCT share price forecasts range from $14.00 to $44.00. On average, they anticipate the company's stock price to reach $28.25 in the next year. This suggests a possible upside of 67.0% from the stock's current price.
View analysts price targets for ARCT
or view top-rated stocks among Wall Street analysts.

How have ARCT shares performed in 2022?

Arcturus Therapeutics' stock was trading at $37.01 at the start of the year. Since then, ARCT stock has decreased by 54.3% and is now trading at $16.92.
View the best growth stocks for 2022 here
.

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our ARCT earnings forecast
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.40) by $0.65. The biotechnology company earned $2.44 million during the quarter, compared to the consensus estimate of $26.70 million. Arcturus Therapeutics had a negative net margin of 284.78% and a negative trailing twelve-month return on equity of 80.43%. During the same period last year, the firm earned ($0.92) earnings per share.

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY).

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (13.47%), State Street Corp (10.31%), ARK Investment Management LLC (8.21%), BlackRock Inc. (7.40%), Sumitomo Mitsui Trust Holdings Inc. (5.49%) and Vanguard Group Inc. (5.05%). Insiders that own company stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $16.92.

How much money does Arcturus Therapeutics make?

Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $448.26 million and generates $12.40 million in revenue each year. The biotechnology company earns $-203,670,000.00 in net income (profit) each year or ($5.56) on an earnings per share basis.

How many employees does Arcturus Therapeutics have?

The company employs 177 workers across the globe.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com.

This page (NASDAQ:ARCT) was last updated on 12/10/2022 by MarketBeat.com Staff